<DOC>
	<DOCNO>NCT00310388</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability long-term therapy retigabine administer adjunctive therapy adult epilepsy patient partial-onset seizure , complete VRX-RET-E22-302 double-blind study . The efficacy long-term treatment retigabine patient quality life also assess .</brief_summary>
	<brief_title>Open-Label Extension Study Phase 3 VRX-RET-E22-302 Double-Blind Trial . 115097</brief_title>
	<detailed_description>This Phase 3 trial open-label extension study placebo-controlled , double-blind VRX-RET-E22-302 trial . Patients complete VRX-RET-E22-302 trial meet inclusion exclusion criterion treat 600-1200 mg/day retigabine adjunct therapy current antiepileptic drug ( AEDs ) vagal nerve stimulation . Treatment continue retigabine commercially available , program discontinue . Patients recruit 55-60 site Europe , Israel , Australia , South Africa . The safety tolerability long-term therapy retigabine administer adjunctive therapy adult epilepsy patient partial-onset seizure evaluate . In addition , efficacy long-term treatment retigabine patient quality life assess .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Patient successfully complete Maintenance Transition phase Study VRXRETE22302 treatment partialonset seizures Patient expect benefit participation study opinion Investigator . Patient meet withdrawal criterion previous VRXRETE22302 study experience ongoing serious adverse event . Patient receive investigational drug use experimental device addition Retigabine treatment epilepsy medical condition . Patient condition would prevent compliance study procedure proper report adverse event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Partial Seizures</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>RTG115097</keyword>
	<keyword>Complex Partial Seizures</keyword>
	<keyword>Anticonvulsant</keyword>
	<keyword>Potassium Channels</keyword>
	<keyword>Epilepsies , Partial</keyword>
</DOC>